BioMarin Paid $270M for a Drug That Can't Fix Bones

But mice aren't children. And raising a biomarker in the blood doesn't guarantee that benefit reaches the skeleton. Regulators had already signaled that PPi alone would need to be backed up by consistent clinical trends. Those trends didn't materialize.

The result is a drug that proves the science is right but can't prove the medicine works. That's a painful place to be.

A Deal That Made Sense (Until It Didn't)

Rewind to May 2025. BioMarin announces the Inozyme acquisition at $4.00 per share, a roughly 196% premium over Inozyme's last closing price. The deal is unanimously approved by both boards. No financing conditions; BioMarin pays from its cash pile.

The logic was sound on paper. BioMarin is the rare disease company that practically invented enzyme replacement therapy, with products like Vimizim, Naglazyme, and Palynziq already on the market in about 80 countries. Inozyme was a clinical-stage company with no commercial infrastructure. BioMarin could plug BMN 401 into its global sales machine and potentially launch by 2027.

RBC analyst Luca Issi called the deal one that "makes total sense" at the time, though he noted it wouldn't significantly move the needle for BioMarin overall. At $270 million against BioMarin's approximately $1.2 billion cash position and approximately $2.85 billion in annual revenue, this was a modest, focused bet.

That framing now cuts both ways. The bet was small enough that losing it won't sink BioMarin. But it's big enough to sting, and it raises awkward questions about due diligence on biomarker-driven programs.

The Write-Down Clock Is Ticking

BioMarin's stock dropped about 4% on the news. Zacks maintained a Hold rating. The market reaction was measured, not panicked, which tells you something: Wall Street had already priced this as a lottery ticket rather than a sure thing.

But the accounting implications are harder to dodge. BMN 401 was Inozyme's primary asset. If the registrational path is broken (and right now, it looks bent at best), BioMarin will likely need to impair the acquired intangible assets, potentially writing down a large chunk of that $270 million.

BioMarin's own SEC filings acknowledge it can't predict future asset impairments with "reasonable certainty." That's corporate-speak for "we know this can happen." Any write-down would hit GAAP earnings but probably get excluded from the non-GAAP metrics that drive most valuation models. The company's target of 40% non-GAAP operating margin in 2026 should survive intact.

Financially manageable? Yes. Strategically embarrassing? Also yes.

What Comes Next

BioMarin says it will keep analyzing the dataset and engage with regulators on BMN 401's future. There are a few potential lifelines.

First, the drug is also being studied in infants with ENPP1 deficiency through separate ENERGY trials. Infant-onset disease looks different from childhood rickets, and the endpoints are different too. A win there could salvage some value. Second, BioMarin could try to negotiate a narrower regulatory claim, perhaps focused on biomarker correction in the highest-risk patients where mortality is the primary concern. It's a long shot, but regulators sometimes flex for ultra-rare diseases with no alternatives.

The company also has INZ-701 programs in ABCC6 deficiency (a related calcification disorder) and calciphylaxis. Those could theoretically carry forward, though they're earlier stage and won't replace the lost ENPP1 pediatric opportunity anytime soon.

The Bigger Picture for BioMarin

The good news: BioMarin isn't a one-trick pony. The company just closed a $4.8 billion acquisition of Amicus Therapeutics, adding two approved products (Galafold for Fabry disease, Pombiliti/Opfolda for Pompe disease) to its portfolio. Its VOXZOGO franchise for skeletal conditions is expanding into five new indications. Revenue guidance sits at $3.1 to $3.2 billion for 2025.

The BMN 401 failure is a bruise, not a broken bone (pun grimly intended). But it's a reminder that in rare disease, strong biology and strong data aren't always the same thing. BioMarin bet $270 million that a biomarker would translate to clinical benefit. The enzyme did its job in the blood. It just couldn't do its job in the bones.

For the roughly 37,000 patients worldwide estimated to have ENPP1 deficiency, most of them still undiagnosed, the wait for a real treatment continues. That's the part that stings the most.

BMS Is Printing Money Right Now. The Clock Is Ticking.

Bristol Myers Squibb just crushed Q2 estimates and hiked its 2026 forecast by billions, thanks to a blood thinner that won't quit and a new drug lineup firing on all cylinders. There's just one problem: the biggest patent cliff in pharma history is about 18 months away.